Sunday, 22 July 2012

The healthy side of bananas: The underrated fruit

According to Japanese Scientific Research, full ripe banana with dark patches on yellow skin produces a substance called TNF (Tumor Necrosis Factor) which has the ability to combat abnormal cells. The more darker patches it has the higher will be its immunity enhancement quality; Hence, the riper the banana the better the anti-cancer quality.
Yellow skin banana with dark spots on it is 8x more effective in enhancing the property of white blood cells than green skin version.




We knew bananas were good for you but this we didn’t know.
The fully ripe banana produces a substance called TNF, which has the ability to combat abnormal cells.
As the banana ripens, it develops dark spots or patches on the skin. The more dark patches it has, the higher will be its’ immunity enhancement quality.
Hence, the Japanese love bananas for a good reason…
According to a Japanese scientific research, banana contains TNF, which has anti-cancer properties.
The degree of anti-cancer effect corresponds to the degree of ripeness of the fruit, i.e. the riper the banana, the better the anti-cancer quality…
In an animal experiment carried out by a professor in Tokyo U comparing the various health benefits of different fruits, using banana, grape, apple, water melon, pineapple, pear and persimmon, it was found that banana gave the best results. It increased the number of white blood cells, enhanced the immunity of the body and produced anti-cancer substance TNF.
The recommendation is to eat 1 to 2 bananas a day to increase your body immunity to diseases like cold, flu and others.
According to the Japanese professor, yellow skin bananas with dark spots on it are 8 times more effective in enhancing the property of white blood cells than the green skin version. 


Monday, 16 July 2012

Molecule in immune system 'may help fight skin cancer'


Molecule in immune system 'may help fight skin cancer'

   
Researchers, including one of Indian origin, have found that high expression of a cell-signalling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
After observing mice without genes responsible for development of an immune cell called T helper cell 17 (TH17), the researchers from Brigham and Women’s Hospital (BWH) found that these mice had significant resistance to melanoma tumour growth, suggesting that blockade of the TH17 cell pathway favoured tumour inhibition. The researchers also noticed that the mice expressed high amounts of interleukin-9.
"These were unexpected results, which led us to examine a possible contribution of interleukin-9 to cancer growth suppression.” Rahul Purwar said.
The researchers next treated melanoma-bearing mice with T helper cell 9 (TH9), an immune cell that produces interleukin-9. They saw that these mice also had a profound resistance to melanoma growth. This is the first reported finding showing an anti-tumour effect of TH9 cells.
Moreover, the researchers were able to detect TH9 cells in both normal human blood and skin, specifically in skin-resident memory T cells and memory T cells in peripheral blood mononuclear cells. In contrast, TH9 cells were either absent or present at very low levels in human melanoma. This new finding paves the way for future studies that will assess the role of interleukin-9 and TH9 cells in human cancer therapy.
Melanoma is the most dangerous form of skin cancer. It is curable if recognized and treated early. The study has been published online in Nature Medicine.

Sunday, 24 June 2012

A NEW CLUE TO CURE DIABETIES!!


Finding holds potential for drug targeting to treat diabetes


Schematic represenation of pancreatic islets from Wdr 13 gene intact mouse (left) and Wdr 13 gene knockout mouse (right)Schematic represenation of pancreatic islets from Wdr 13 gene intact mouse (left) and Wdr 13 gene knockout mouse (right)







Scientists from the Centre for Cellular and Molecular Biology (CCMB) have found that knocking out a gene in mice led to higher insulin production and better glucose tolerance. The finding holds the potential for drug targeting to treat diabetes.
The team, led by Satish Kumar, serendipitously found that knocking out the WDR13 gene, resulted in hyper insulin secretion and improved glucose clearance. The team genetically engineered a mouse by knocking out the gene, which is conserved in all organisms from fishes to humans and encodes a protein. It is a member of the WD-repeat proteins that have a wide range of cellular functions.
The increase in insulin production was caused by enhanced beta cell proliferation and higher islet mass in pancreas. This gene was knocked out for the first time, said Vijay Pratap Singh, lead author of the study, which was published online in science journal PLoS ONE recently.
The test animals went on to develop mild obesity as they aged. Interestingly, however, they continued to have better glucose clearance in spite of mild obesity. It was not yet known if the obesity was due to higher insulin levels or some different function of the gene.
Dr. Kumar told The Hindu that by inhibiting the functions of this protein, insulin production could be enhanced.
“Indirectly, we discovered a drug target because now we know that if we interfere with this protein, there is more insulin,” he said.
However, he noted that there was a flipside to the finding. While there was no problem with the ‘knockout' mice up to one year, subsequently, their cell proliferation increased — such phenomenon lead to tumours. The researchers were not aware of the WDR13's function of regulating cell division.
The real challenge would be to develop a drug, which would interfere in a limited way with the functioning of the gene, so as to avoid rapid cell proliferation.
Dr. Kumar said their research initially was not related to diabetes. “We were doing basic biology. This is side implication with an interesting lead.”
Describing the finding as a “good and useful observation,” CCMB director Ch. Mohan Rao said: “We are trying to decipher the cause for increase in fatty cells and the pancreatic cells.” There was scope for drug development if the two could be separated.

Saturday, 12 May 2012

Garlic Power 

Make it your principal supplement. Photo: Special Arrangement.
Make it your principal supplement. Photo: Special Arrangement.
Garlic's medicinal properties are well known; so go ahead and add it to your diet.
For centuries garlic has been used as a medicinal and culinary substance in India, China, Greece and other countries. It has been used as a salve for everything from headaches to colds to infections and healing wounds. To some, however, the strong flavour of garlic is not very appealing; in fact repelling. Therefore, although garlic is a widely available spice, it is not very popular in some households.
Garlic does not make significant nutritional contribution to the diet because the quantities added to recipes are small. But even these nano amounts make a big difference to one's health.
The biological benefits and the distinct odour of garlic are attributed to the many sulphur containing compounds; one of which is Alliin. This compound is converted to Allicin when garlic is crushed. Allicin is, perhaps, the principal bioactive compound present even in processed garlic.
Limited evidence supports an association between garlic consumption and a reduced risk of colon, prostate, oesophageal, larynx, oral, ovary and other cancers. This is due to diallylsulde, a potent bioactive component. Besides, the plant can also accumulate selenium, a trace element known to possess anti-cancer properties, from the soil.
Curtailing cardiac diseases
One inexpensive way of curtailing cardiovascular diseases is to use generous amounts of garlic in cooking. Garlic consumption inhibits the progression of cardiovascular diseases. It can bring about small reductions in blood pressure. Some studies have shown it to modestly lower cholesterol levels, which is also a protection against cardiac diseases. Animal experiments have associated garlic ingestion with reduction in triglyceride and LDL cholesterol, both of which contribute to atherosclerosis and heart diseases. Garlic, like aspirin, can reduce the tendency of blood to coagulate and form clots. Many human studies on garlic have shown it has the ability to dissolve blood clots. Pharmaceutical supplements are often used by patients with cardiac and vascular diseases.
Garlic can reduce homocysteine levels in blood. This toxic compound damages the cells that line the blood vessels, induces blood clots, loss of cognition and causes death of nerve cells. People with dementia and Alzheimer's disease have elevated blood homocysteine levels. Damage to nerve cells in Alzheimer's disease is also due to elevated oxidative stress induced by free radicals. By scavenging free radicals, garlic offers protection from neuronal death, dementia and Alzheimer's disease.
Garlic is also called ‘Russian penicillin'. Fresh — but not stored or cooked garlic — is an antimicrobial agent against a variety of micro-organisms, including H. Pylori, implicated in gastric cancers. Topical application of garlic is effective in treating ringworm. Many studies have shown that garlic has antifungal and antiviral effects.
Adverse effects
Are there any adverse effects associated with taking garlic? In some, it can cause mild stomach discomfort, especially when taken on an empty stomach. Add garlic to meals or sprinkle it on pasta, soups or even sambhar and chutneys. Swallow a clove of crushed garlic with water. The common side effect is “Garlicky Breath”.
Since garlic is also a blood thinner, people who take aspirin should be careful when including garlic regularly in their diets. Also discontinue garlic at least a week before any surgery.
How much? One clove of medium-sized garlic daily provides health boosting effects. Numerous over-the-counter supplements are available as are enteric-coated tablets. Those who don't like the strong flavour can try deodorised capsules. It is indeed the cornerstone of good health.
Did you know?
Garlic can inhibit changes in the DNA and scavenge free radicals; both are implicated in cancers. It can also limit the transition of a normal cell into a cancerous cell, inhibit the growth of cancer cells, and even destroy the cancer cells.
Garlic can reduce plaque formation in blood vessels and help lower blood sugar levels.
Because of its antioxidant properties, regular intake of garlic can reduce the incidence of many age-related disorders such as cataracts, arthritis, and rejuvenate skin and promote blood circulation.
Garlic also promotes liver health and protects the liver from many environmental toxins and drugs such as the commonly used analgesic agent, paracetamol (Crocin, Tylenol).

Did those bacteria really dine on lethal arsenic?

Felisa Wolfe-Simon processing mud from Mono Lake to inoculate media to grow microbes on arsenic. File photo
Felisa Wolfe-Simon processing mud from Mono Lake to inoculate media to grow microbes on arsenic. File photo
A scientist uses ‘open science' to find an answer
It was research that appeared set to turn the biological world on its head. A paper published online by the journal Science in December 2010 described a strain of bacteria that not only thrived in high levels of arsenic but appeared to incorporate it in its biomolecules, including DNA, displacing phosphorus that all other known forms of life utilise.
The U.S. space agency, the National Aeronautics and Space Administration (NASA), which had funded the research, loudly trumpeted the discovery. "The definition of life has just expanded," exulted a senior agency official in a press release.
But the paper by Felisa Wolfe-Simon and others failed to convince their peers in the scientific community. Instead, what followed was an outcry from scientists about flaws in the research. There was good reason, they said, to doubt that the bacterium was using arsenic in its DNA.
Science, according to its Editor-in-Chief, Bruce Alberts, received “a wide range of correspondence that raised specific concerns” about the paper's research methods and interpretation of results. In May 2011, the journal took the unusual step of publishing online eight technical comments that raised a number of issues.
But the question remained – shouldn't someone else try to replicate the experiment using methods that avoided the pitfalls of the earlier work? It was not an alluring prospect, considering that the most likely outcome would be to merely corroborate the flaws that had already been pointed out.
Rosemary Redfield, a microbiologist at University of British Columbia in Canada, decided to take on the task. In a post on her blog ‘RRResearch', which received a good deal of attention, she had criticised the Science paper as “lots of flim-flam, but very little reliable information.”
“I've been saying that researchers shouldn't invest the time and resources needed to test Wolfe-Simon et al's claims because of the vanishingly small probability that they are correct,” she remarked in a blog post in May last year.  “But I'm having second thoughts because the most important claims can, I think, be very easily tested.”
Having got the bacterial strain from the original group of researchers, Dr. Redfield set about planning and carrying out experiments in a remarkably different fashion. The experiments she wanted to do, the problems that cropped up and the results she got were all written up on her blog. “One of the thing that had always been unusual about my blog was that I was writing openly about the experiments that I was doing before they were published,” she said on a recent episode of the podcast ‘This Week in Microbiology'. It was important that the process of science be made much more open. It was also a useful way to clarify her thinking.
By January this year, Dr. Redfield and her collaborators at Princeton University in the U.S. had finished the lab work and prepared a paper. The paper was submitted to Science. But she also did something that is common enough in physics but rare in biology. The full manuscript was posted on arXiv.org, the preprint server that is freely accessible.
“The advantage of arXiv is that the physicists all use it,” she remarked on the podcast. So Science would have had to deal with physicists posting papers there before or after they submitted them for publication. Indeed, the editor atScience handling their paper said that the journal had no problem with the manuscript being put on arXiv.
Science later responded with a provisional acceptance and comments from three reviewers. The manuscript was revised in the light of those comments and sent back to the journal.
But Dr. Redfield has also posted the full reviewers' comments on a web site and the revised manuscript was made available on arXiv.
Asked on the podcast whether the reviewers' comments could be released publicly, she responded, “I don't see why not.” There was nothing to indicate that those comments were to be kept in confidence. As for their finding, the manuscript declares that there was no sign that the bacterium was able to grow by using arsenic or that the element had been incorporated in its DNA. “On April 13, we submitted the revised version [of the manuscript to Science], and we're waiting with fingers crossed for final acceptance,” said Dr. Redfield on her blog.

Sunday, 6 May 2012


Cause of male baldness found

The proof: The enzyme level in the scalp of balding men rises nearly three times.
Photo: K.R. Deepak

Prostaglandin D2, and its derivative inhibit hair growth
Scientists have finally identified the culprits that are responsible for causing baldness in men. They are prostaglandin D2, also known as PGD2 and its derivative (15-dPGJ2). Incidentally, PGD2 and its derivative were found to show the same effect in mice as well.
The results are published today (March 22) in Science Translational Medicine.
Researchers from the University of Pennsylvania found that the PGD2 inhibits hair growth. In fact, its level “increases immediately preceding the regression phase,” they write. Its level in the scalp of balding men increases nearly three times compared to those who are not bald. “The absolute level of PGD2 was 16.3 ng/g tissue in balding scalp and 1.5 ng/g tissue in haired scalp,” the paper notes.
The scientists tested their hypothesis using explanted human hair follicles in culture for a week. They used different amounts of both PGD2 and its derivative to check their effects.
At low levels (5 micromolar) of the medium, PGD2 and its derivative “significantly inhibited hair growth.” The hair became shorter when 10 micromolar of PGD2 was used. But at the same concentration, the derivative “completely inhibited all hair growth.”
Different prostaglandins have been known to regulate and increase hair growth. In fact one such prostaglandin has been approved by the FDA to enhance hair growth in human eyelashes. And another is supposed to protect mice from radiation-induced hair loss.
But this study has shown that both in mouse and human skin a balance between the two prostaglandins — PGE2 and PGD2 — is required. There may be other causes for baldness, they note.
The study provides the first ray of hope to people who show early signs of balding. The authors suggest that the level of PGE2 should be increased while inhibiting PGD2 signalling. “Our findings also suggest that supplemental PGE2 could be therapeutic,” they write. They also note that increasing its level in the bald scalp can go as far as overcoming the inhibitory effect of PGD2. The act of inhibiting PGD2 level “may prevent miniaturization and provide benefit to those in the process of balding.”
But they have almost dashed the hopes of people who are already bald. “It is unclear whether men who are already bald will regrow hair,” they write.
This article is corrected for a factual error. Prostaglandin D2 (PGD2) was wrongly mentioned as a protein.

Universal cancer vaccine developed


Scientists claim to have developed a universal cancer vaccine that can train patients’ own bodies to seek out and destroy tumour cells.
A team from Tel Aviv University and drug company Vaxil Biotheraputics say the therapy targets a molecule found in 90 per cent of all cancers, and could soon pave the way for a universal injection that allows patients’ immune systems to fight off common cancers including breast and prostate cancer.
Preliminary results from early clinical trials have shown that the vaccine can trigger an immune response in patients and reduce levels of disease, The Sunday Telegraph reported.
Now, the scientists hope to conduct larger trials in patients to prove it can be effective against a range of different cancers.
In fact, they believe it could be used to combat small tumours if they are detected early enough or to prevent the return of the disease in patients, who have undergone other forms of treatment such as surgery.
Cancer cells usually evade patient’s immune systems because they are not recognised as being a threat. While the immune system usually attacks foreign cells such as bacteria, tumours are formed of patient’s own cells that malfunctioned.
The scientists have, however, found that a molecule called MUC1, found in high amounts on the surface of cancer cells, can be used to help immune system detect tumours.
The vaccine uses a small section of the molecule to prime the immune system so that it can identify and destroy cancer cells, say the scientists.